Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Diabetes Care Publish Ahead of Print published online ahead of print August 17, 2007
DOI: 10.2337/dc07-1110
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc07-1110v1
30/11/2922    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brignardello, E.
Right arrow Articles by Boccuzzi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brignardello, E.
Right arrow Articles by Boccuzzi, G.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

Dehydroepiandrosterone administration counteracts oxidative imbalance and AGE formation in type 2 diabetic patients

Enrico Brignardello, MD1, Cristina Runzo, MD2, Manuela Aragno, PhD3, Maria Graziella Catalano, MD4, Maurizio Cassader, PhD2, Paolo Cavallo Perin, MD2 and Giuseppe Boccuzzi, MD1,,4

1Oncological Endocrinology Unit, San Giovanni Battista Hospital, Turin, Italy
2Department of Internal Medicine, University of Turin, Italy
3Department of Experimental Medicine and Oncology, University of Turin, Italy
4Department of Clinical Pathophysiology, University of Turin, Italy

giuseppe.boccuzzi{at}unito.it

ABSTRACT

Objective: Dehydroepiandrosterone (DHEA) has been shown to prevent oxidative stress in several "in vivo" and "in vitro" models. The study aimed to evaluate the effects of DHEA administration on oxidative stress, pentosidine concentration and TNF{alpha}/TNF{alpha} receptor system activity in patients with type 2 diabetes.

Research Design and Methods: Twenty patients were enrolled in the study and randomly assigned to the DHEA (n = 10) or placebo (n = 10) group. Twenty healthy sex- and age-matched subjects with normal glucose levels served as controls. DHEA was given as a single daily dose of 50 mg, for 12 weeks.

Results: Oxidative stress parameters were significantly higher in diabetic patients versus controls. Pentosidine levels, as well as sTNF-RI and sTNF-RII, were also higher in diabetic patients. After DHEA, plasma levels of ROS and HNE dropped by 53% and 47% respectively, whereas the non-enzymatic antioxidants GSH and Vitamin E increased (+ 38 and +76%, respectively). The same changes in oxidative parameters were detected in peripheral blood mononuclear cells (PBMC). DHEA treatment also induced a marked decrease of pentosidine plasma concentration in diabetic patients (- 50%). Moreover, the TNF{alpha}/TNF{alpha} receptor system was shown to be less activated after DHEA treatment, both in plasma and in PBMC.

Conclusions: Data indicate that DHEA treatment ameliorates the oxidative imbalance induced by hyperglycaemia, down-regulates the TNF{alpha}/TNF{alpha} receptors system and prevents AGE formation, suggesting a beneficial effect on the onset and/or progression of chronic complications in type 2 diabetic patients.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.